نتائج البحث

Metabolite profiling of foslevodopa/foscarbidopa in plasma of healthy human participants by LC-HRMS indicates no major differences compared to administration of levodopa/carbidopa intestinal gel.

• Authors : Savaryn JP; AbbVie Inc., North Chicago, Illinois, USA.; Smith RL

Subjects: Carbidopa*/Carbidopa*/Carbidopa*/pharmacokinetics ; Parkinson Disease*/Parkinson Disease*/Parkinson Disease*/drug therapy; Humans

• Source: Pharmacology research & perspectives [Pharmacol Res Perspect] 2024 Apr; Vol. 12 (2), pp. e1190.Publisher: John Wiley & Sons Ltd, British Pharmacological Society and American Society for Pharmacology and Experimental Therapeutics Country of Publication: United States

تفاصيل العنوان

Starting with 24-h levodopa carbidopa intestinal gel at initiation in a large cohort of advanced Parkinson's disease patients.

• Authors : Szatmári S; 2nd Clinic of Neurology, Târgu Mures County Emergency Clinical Hospital, Târgu Mureș, Romania.; University of Medicine, Pharmacy, Science and Technology of Târgu Mures, George Emil Palade, Gh. Marinescu Street No 38, 540142, Târgu Mures, Romania.

Subjects: Carbidopa*/Carbidopa*/Carbidopa*/therapeutic use ; Parkinson Disease*/Parkinson Disease*/Parkinson Disease*/drug therapy; Humans

• Source: Scientific reports [Sci Rep] 2024 Feb 14; Vol. 14 (1), pp. 3676. Date of Electronic Publication: 2024 Feb 14.Publisher: Nature Publishing Group Country of Publication: England NLM ID: 101563288 Publication Model: Electronic Cited Medium: Internet ISSN:

تفاصيل العنوان

Quantitative Colorimetric Sensing of Carbidopa in Anti-Parkinson Drugs Based on Selective Reaction with Indole-3-Carbaldehyde.

• Authors : Palladino P; Department of Chemistry 'Ugo Schiff', University of Florence, Via della Lastruccia 3-13, 50019 Sesto Fiorentino, Italy.; Rainetti A

Subjects: Carbidopa*/Carbidopa*/Carbidopa*/analysis ; Carbidopa*/Carbidopa*/Carbidopa*/therapeutic use ; Quality of Life*

• Source: Sensors (Basel, Switzerland) [Sensors (Basel)] 2023 Nov 13; Vol. 23 (22). Date of Electronic Publication: 2023 Nov 13.Publisher: MDPI Country of Publication: Switzerland NLM ID: 101204366 Publication Model: Electronic Cited Medium: Internet ISSN: 1424-8220

تفاصيل العنوان

Development and Validation of a New LC-MS/MS Bioanalytical Method for the Simultaneous Determination of Levodopa, Levodopa Methyl Ester, and Carbidopa in Human Plasma Samples.

• Authors : Molteni L; Laboratory of Neurological Biochemistry and Neuropharmacology, Fondazione IRCCS Istituto Neurologico Carlo Besta, 20133 Milano, Italy.; Charlier B

Subjects: Levodopa* ; Carbidopa*/Carbidopa*/Carbidopa*/pharmacology; Male

• Source: Molecules (Basel, Switzerland) [Molecules] 2023 May 23; Vol. 28 (11). Date of Electronic Publication: 2023 May 23.Publisher: MDPI Country of Publication: Switzerland NLM ID: 100964009 Publication Model: Electronic Cited Medium: Internet ISSN: 1420-3049

تفاصيل العنوان

Comparison of the effectiveness, safety, and costs of anti-Parkinson drugs: A multiple-center retrospective study.

• Authors : Li W; Department of Pharmacy, Peking University Third Hospital, Beijing, China.; Department of Pharmacy, The Eighth Affiliated Hospital, Sun Yat-Sen University, Shenzhen, China.

Subjects: Levodopa*/Levodopa*/Levodopa*/adverse effects ; Parkinson Disease*/Parkinson Disease*/Parkinson Disease*/drug therapy; Humans

• Source: CNS neuroscience & therapeutics [CNS Neurosci Ther] 2024 Apr; Vol. 30 (4), pp. e14531. Date of Electronic Publication: 2023 Nov 20.Publisher: Wiley-Blackwell Country of Publication: England NLM ID: 101473265 Publication Model: Print-Electronic Cited Medium: Internet ISSN:

تفاصيل العنوان

Piperine improves levodopa availability in the 6‐OHDA‐lesioned rat model of Parkinson's disease by suppressing gut bacterial tyrosine decarboxylase.

• Authors : Hu, Xiaolu¹ (AUTHOR); Yu, Lan¹ (AUTHOR); Li, Yatong¹ (AUTHOR)

• Source: CNS Neuroscience & Therapeutics. Feb2024, Vol. 30 Issue 2, p1-14. 14p.

تفاصيل العنوان

The Use of Liquid Sinemet in Routine Clinical Practice of Advanced Parkinson's Disease: A Comparison of Available Options.

• Authors : Sung CB; Clinical Research Centre for Movement Disorders and Gait, Parkinson's Foundation Center of Excellence, Monash Health, Kingston Centre, Melbourne, Australia.; Danoudis M

Subjects: Carbidopa* ; Parkinson Disease*/Parkinson Disease*/Parkinson Disease*/complications; Humans

• Source: Journal of Parkinson's disease [J Parkinsons Dis] 2023; Vol. 13 (4), pp. 609-617.Publisher: IOS Press Country of Publication: Netherlands NLM ID: 101567362 Publication Model: Print Cited Medium: Internet ISSN: 1877-718X

تفاصيل العنوان

Adverse effects of levodopa/carbidopa intrajejunal gel treatment: A single-center long-term follow-up study.

• Authors : Rus T; Department of Neurology, UMC Ljubljana, Ljubljana, Slovenia.; Medical Faculty, University of Ljubljana, Ljubljana, Slovenia.

Subjects: Carbidopa*/Carbidopa*/Carbidopa*/adverse effects ; Parkinson Disease*/Parkinson Disease*/Parkinson Disease*/drug therapy; Antiparkinson Agents/Antiparkinson Agents/Antiparkinson Agents/adverse effects

• Source: Acta neurologica Scandinavica [Acta Neurol Scand] 2022 Nov; Vol. 146 (5), pp. 537-544. Date of Electronic Publication: 2022 Jul 28.Publisher: Wiley-Blackwell Country of Publication: Denmark NLM ID: 0370336 Publication Model: Print-Electronic Cited Medium: Internet ISSN:

تفاصيل العنوان

Why do 'OFF' periods still occur during continuous drug delivery in Parkinson's disease?

• Authors : Rota S; Department of Basic and Clinical Neurosciences, Institute of Psychiatry, Psychology and Neuroscience, King's College London, London, UK. .; Parkinson's Foundation Centre of Excellence, King's College Hospital, London, UK. .

Subjects: Carbidopa*/Carbidopa*/Carbidopa*/therapeutic use ; Parkinson Disease*/Parkinson Disease*/Parkinson Disease*/drug therapy; Antiparkinson Agents/Antiparkinson Agents/Antiparkinson Agents/therapeutic use

• Source: Translational neurodegeneration [Transl Neurodegener] 2022 Oct 13; Vol. 11 (1), pp. 43. Date of Electronic Publication: 2022 Oct 13.Publisher: BioMed Central Country of Publication: England NLM ID: 101591861 Publication Model: Electronic Cited Medium: Print ISSN: 2047-9158

تفاصيل العنوان

An Overview of Cannabidiol as a Multifunctional Drug: Pharmacokinetics and Cellular Effects.

• Authors : Martinez Naya N; Robert M. Berne Cardiovascular Research Center, Division of Cardiovascular Medicine, School of Medicine, University of Virginia, Charlottesville, VA 22903, USA.; Kelly J

Subjects: Cannabidiol*/Cannabidiol*/Cannabidiol*/pharmacology ; Cannabidiol*/Cannabidiol*/Cannabidiol*/therapeutic use ; Hallucinogens*

• Source: Molecules (Basel, Switzerland) [Molecules] 2024 Jan 18; Vol. 29 (2). Date of Electronic Publication: 2024 Jan 18.Publisher: MDPI Country of Publication: Switzerland NLM ID: 100964009 Publication Model: Electronic Cited Medium: Internet ISSN: 1420-3049

تفاصيل العنوان